Drug intelligence / Profile preview

YT-II-100

Development stage: Unknown
Lead developer: UT Southwestern Medical Center

Overview

YT-II-100: sourced facts only. name: "Here, we test the impact of YT-II-100, a novel inhibitor of CPSF3." [PMID:42214474]; target: "Here, we test the impact of YT-II-100, a novel inhibitor of CPSF3." [PMID:42214474]; developer: "UT Southwestern Medical Center, Departments of Pharmacology and Biochemistry, 6001 Forest Park Road, Dallas, TX 75390-9041, United States." [PMID:42214474]

Targets

CPSF3 (Cleavage and polyadenylation specificity factor 3)

Beyond the preview

Go deeper on YT-II-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YT-II-100.